Warp: I've never flipped on being long on AMBS. I've just criticized Gerald for his communications leading up to the July Conferences and the partnership agreement that never happened at the "end of summer" for Lympro. Seeing our stock dive from .193 cents to below .08 cents for the entire second half of the year generated criticisms from me and others. That doesn't mean we still weren't long on the stock, but we were dismayed at how 2014 turned out.

But you're right, it does take a certain "intellectual" firepower and honesty for readers to discern the difference between longs with genuine criticisms and flippers like Solantey who simply try to profit off of their changing views. People in your "gang" don't seem free enough intellectually to make such distinctions. Your posts are completely determined by your collective "groupthink."